LONDON--(BUSINESS WIRE)-- Over the coming five-year period, transfusion diagnostics practice is bound to be revolutionized owing to a combination of factors. These resultant market changes will offer bright opportunities for new reagent systems and instruments, as well as for a slew of auxiliary products.
New study “Competing in the Global Blood Banking Market” created by Venture Planning Group (VPG) is designed to identify and evaluate emerging opportunities in the global blood banking market during the next five years.
The report explores future marketing and technological trends in the key geographies – the US, Europe (France, Germany, Italy, Spain, and the UK) and Japan. It provides sales and market share estimates for major reagent and instrument suppliers by country and product; test volume and sales forecasts for over 40 transfusion diagnostic tests (including NAT) by country and market segment; instrument placements and installed base by manufacturer and model; comparison of major automated and semi-automated analyzers. The profiles of the top competitors and emerging market entrants developing innovative technologies and products, along with reviews of specific product and marketing opportunities expected to face suppliers during the next decade are also covered.
Companies discussed include Abbott, Beckman Coulter/Danaher, Becton Dickinson, Biokit, BioMerieux, Bio-Rad, Diagast, DiaSorin, Fujirebio, Gen-Probe, Grifols, Immucor, Innogenetics, Ortho-Clinical Diagnostics, Orchid CellMark, Novartis Diagnostics, Proteome Sciences, Roche, Siemens, and Tecan.
Title: Competing in the Global Blood Banking Market
Published: February, 2013
Price: US$ 32,500.00
More Diagnostics & Diseases Market Studies by VPG Include:
More new studies by VPG can be found at http://marketpublishers.com/members/vpg/info.html